Eli Lilly LLY Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $7.4B+11.4% | $6.64B+18.9% | $5.58B-1.4% | $5.66B+105% | $2.76B-37.4% | ||
| $509M-13.1% | $585.7M+24.6% | $470M-1.7% | $478.3M+3.3% | $463M-4.6% | ||
| $161M+18.3% | $136.1M-9.9% | $151.1M-18.2% | $184.8M+20.0% | $154M+8.2% | ||
| $1.48B+97.6% | $748.1M— | —— | $1.07B+173% | $392M-59.4% | ||
| —— | $1.17B0.0% | $1.17B0.0% | $1.17B0.0% | $1.17B+86.3% | ||
| —— | $2.55B0.0% | $2.55B0.0% | $2.55B0.0% | $2.55B+290% | ||
| —— | $1.65B0.0% | $1.65B0.0% | $1.65B0.0% | $1.65B+98.4% | ||
| -$175M— | —— | $302.3M— | —— | $474M-28.4% | ||
| —— | $1.75B0.0% | $1.75B0.0% | $1.75B0.0% | $1.75B+225% | ||
| $5.33B+65.4% | $3.22B-63.5% | $8.84B+186% | $3.09B+85.3% | $1.67B-32.7% | ||
| $2.33B-8.7% | $2.55B+22.0% | $2.09B+23.1% | $1.7B+12.4% | $1.51B+0.9% | ||
| $1.06B+848% | $111.6M-79.7% | $549.4M— | $0— | $0-100% | ||
| $297M+134% | $127M-15.4% | $150.1M-12.2% | $170.9M-13.2% | $197M+29.7% | ||
| $31M+155% | -$56.8M-283% | $31M-77.2% | $135.8M+222% | -$111M-116% | ||
| $584M— | —— | $655.7M+326% | $153.8M-90.2% | $1.57B— | ||
| -$3.92B-39.7% | -$2.8B+6.0% | -$2.98B-62.6% | -$1.83B+45.3% | -$3.35B-74.5% | ||
| $1.55B+15.1% | $1.35B0.0% | $1.35B-0.2% | $1.35B+0.1% | $1.35B+15.2% | ||
| $2.36B+56.3% | $1.51B+113% | $708.1M+2.3% | $692.2M-42.3% | $1.2B-41.6% | ||
| $0— | —— | $6.71B— | —— | $6.46B— | ||
| $750M— | —— | —— | $778.1M— | $0-100% | ||
| -$591M-2,255% | -$25.1M+16.9% | -$30.2M+1.6% | -$30.7M+95.5% | -$686M-1,395% | ||
| $1.78B+443,850% | -$400K+100.0% | -$4.09B— | —— | -$1.85B— | ||
| -$3.47B-20.5% | -$2.88B-642% | $531M+143% | -$1.25B-190% | $1.38B— | ||
| $67M— | —— | $31.7M-88.5% | $275.4M+109% | $132M+131% | ||
| -$1.99B— | —— | $6.42B+2,171% | $282.5M+261% | -$175M— | ||
| —— | $1.75B0.0% | $1.75B0.0% | $1.75B0.0% | $1.75B+225% | ||
| $1.48B+97.6% | $748.1M— | —— | $1.07B+173% | $392M-59.4% | ||
| —— | $1.65B0.0% | $1.65B0.0% | $1.65B0.0% | $1.65B+98.4% | ||
| $584M+10.4% | $528.8M-19.4% | $655.7M+326% | $153.8M-90.2% | $1.57B+733% | ||
| $1.06B+848% | $111.6M-79.7% | $549.4M— | $0— | $0-100% | ||
| $31M+155% | -$56.8M-283% | $31M-77.2% | $135.8M+222% | -$111M-116% | ||
| $204M-51.9% | $423.7M-41.2% | $720.5M+575% | $106.8M-93.9% | $1.76B+599% | ||
| $297M+134% | $127M-15.4% | $150.1M-12.2% | $170.9M-13.2% | $197M+29.7% | ||
| $2.33B-8.7% | $2.55B+22.0% | $2.09B+23.1% | $1.7B+12.4% | $1.51B+0.9% | ||
| -$591M-2,255% | -$25.1M+16.9% | -$30.2M+1.6% | -$30.7M+95.5% | -$686M-1,395% | ||
| $1.78B+443,850% | -$400K+100.0% | -$4.09B— | —— | -$1.85B— | ||
| $3.01B+344% | $677.9M-90.0% | $6.75B+386% | $1.39B+791% | $156M-84.0% | ||
| $3.01B+344% | $677.9M-90.0% | $6.75B+386% | $1.39B+791% | $156M-84.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Eli Lilly generate?
- Eli Lilly (LLY) generated $20.5B in operating cash flow over the trailing twelve months.
- What is Eli Lilly's free cash flow?
- After $8.7B of capital expenditures, Eli Lilly's free cash flow was $11.8B over the trailing twelve months, up 216.4% year over year.
- Where does Eli Lilly's cash flow data come from?
- Every line is extracted from Eli Lilly's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
